Meditor Group LTD Has Lifted Celldex Therapeutics (CLDX) Position By $1.03 Million; Sasol Limited (SSL) Had 4 Bullish Analysts

February 18, 2018 - By Adrian Erickson

Meditor Group Ltd increased Celldex Therapeutics (CLDX) stake by 8.84% reported in 2017Q3 SEC filing. Meditor Group Ltd acquired 512,700 shares as Celldex Therapeutics (CLDX)’s stock declined 11.75%. The Meditor Group Ltd holds 6.31 million shares with $18.05M value, up from 5.80 million last quarter. Celldex Therapeutics now has $319.57M valuation. The stock increased 1.73% or $0.04 during the last trading session, reaching $2.35. About 2.17M shares traded or 86.96% up from the average. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.62% since February 18, 2017 and is downtrending. It has underperformed by 37.32% the S&P500.

Among 7 analysts covering Sasol (NYSE:SSL), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Sasol had 12 analyst reports since September 9, 2015 according to SRatingsIntel. JP Morgan downgraded Sasol Limited (NYSE:SSL) on Tuesday, July 18 to “Neutral” rating. On Tuesday, February 13 the stock rating was upgraded by J.P. Morgan to “Buy”. J.P. Morgan downgraded the stock to “Hold” rating in Tuesday, July 18 report. The stock has “Buy” rating by Citigroup on Wednesday, September 14. The rating was initiated by Credit Suisse with “Outperform” on Monday, September 26. On Wednesday, September 9 the stock rating was upgraded by Citigroup to “Buy”. The company was upgraded on Tuesday, August 16 by Bank of America. The rating was downgraded by Bank of America to “Neutral” on Friday, March 11. The stock of Sasol Limited (NYSE:SSL) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, April 5. The firm has “Hold” rating by Citigroup given on Tuesday, November 28. See Sasol Limited (NYSE:SSL) latest ratings:

13/02/2018 Broker: J.P. Morgan Rating: Buy Upgrade
28/11/2017 Broker: Citigroup Rating: Hold Downgrade

The stock increased 0.77% or $0.26 during the last trading session, reaching $34.18. About 384,370 shares traded or 46.27% up from the average. Sasol Limited (NYSE:SSL) has risen 6.49% since February 18, 2017 and is uptrending. It has underperformed by 10.21% the S&P500.

Sasol Limited operates as an integrated chemicals and energy company. The company has market cap of $18.22 billion. It operates through Mining, Exploration and Production International, Energy, Base Chemicals, and Performance Chemicals divisions. It has a 15.06 P/E ratio. The firm operates coal mines; develops and manages upstream interests in gas and oil exploration and production in Mozambique, South Africa, Australia, Canada, and Gabon; and markets commodity and various performance chemicals, such as organics, inorganics and wax value chains, as well as polymers, solvents, and ammonia fertilizers.

Among 13 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Celldex Therapeutics had 24 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) earned “Market Perform” rating by Leerink Swann on Monday, March 7. The firm earned “Perform” rating on Monday, March 7 by Oppenheimer. The firm earned “Neutral” rating on Monday, March 7 by Guggenheim. H.C. Wainwright reinitiated Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Tuesday, August 1 with “Buy” rating. The firm earned “Buy” rating on Friday, February 26 by Cantor Fitzgerald. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, November 7 report. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Hold” rating given on Thursday, August 31 by Jefferies. H.C. Wainwright maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Wednesday, August 9 with “Buy” rating. The stock has “Neutral” rating by Wedbush on Monday, March 7. H.C. Wainwright maintained the shares of CLDX in report on Tuesday, March 8 with “Buy” rating.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>